



Cholestatic Liver Diseases: From the Bench to Bedside

Guest Editors:

Dr. Agnieszka Kempińska-Podhorodecka

Department of Medical Biology,
Pomeranian Medical University in
Szczecin, Szczecin, Poland

Dr. Ewa Wunsch

Department of Translational
Medicine, Pomeranian Medical
University in Szczecin, Szczecin,
Poland

Deadline for manuscript
submissions:

31 May 2024

Message from the Guest Editors

This Special Issue aims to publish high-quality research papers as well as review articles on recent advances in the understanding of the pathogenesis of PBC and PSC, to provide a clinical picture of these diseases as well as novel treatment modalities. Original unpublished papers that are not currently under review by other journals and peer-reviewed high-quality contributions from conferences are sought.

We invite practitioners and researchers in the areas of basic science and clinical hepatology to contribute to this Special Issue both with original research and review articles, with the aim of providing an overview of the currently available knowledge and new findings on cholestatic liver diseases.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)